Sign Out
50 mg: Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration.
150 mg: In patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO), CASODEX 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy (see Pharmacology: Pharmacodynamics under Actions).
CASODEX 150 mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.
Lanjutkan dengan Google